A Double-blind Study to Investigate Efficacy, Safety and Tolerability of BAY1142524 in Patients With Type II Diabetes and a Clinical Diagnosis of Diabetic Kidney Disease
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 152 participants.
Also called NCT03412006
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 152 participants
- Sponsor
- Registry
-
NCT03412006 -
2017-000656-26
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Bulgaria, Denmark, Finland, Israel, Italy, Spain, Sweden
- Registry status
- Completed
Technical summary
Registry record NCT03412006. Randomized; quadruple masking; primary purpose treatment. Start 2018-02-02 (actual); primary completion 2019-10-02 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Double-blind Study to Investigate Efficacy, Safety and Tolerability of BAY1142524 in Patients With Type II Diabetes and a Clinical Diagnosis of Diabetic Kidney Disease
- Acronym
- CADA DIA
- Condition
- Diabetic Kidney Disease
- Intervention (Drug)
- Fulacimstat (BAY1142524)
- Intervention (Drug)
- Placebo
- Lead sponsor
- Bayer
Record details
- Record id
cardio:ct-nct03412006- Content hash
209dd571ee1b3977ab0bf66c8a9cb6fef4966c197a458c8e47f64dfa48377a63